Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland (fMDA)
Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland
Sponsor: Clinton Health Access Initiative, Eswatini
Listed as NCT02315690, this PHASE3 trial focuses on Malaria and remains completed. Sponsored by Clinton Health Access Initiative, Eswatini, it has been updated 10 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinton Health Access Initiative, Eswatini
- Ministry of Health, Swaziland
- University of California, San Francisco
- University of Texas
For direct contact, visit the study record on ClinicalTrials.gov .